SciBase Holding AB

SciBase initiates pilot with Bare Dermatology to advance skin cancer detection in Texas

September 25, 2023 Published by Roboticulized.com

SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Bare Dermatology to pilot Nevisense in select locations in Texas. Bare Dermatology is a dermatology practice group in the Greater Dallas area, with five offices and a team of nationally renowned dermatologists. The agreement will provide Bare Dermatology with Nevisense, the only FDA-approved test for early melanoma detection at point-of-care.

“At Bare Dermatology, we strive to provide our patients with the highest standard of care. Nevisense can help us to identify melanoma at an early stage, which is critical for improving patient outcomes. Melanoma is a leading cause of death among skin cancers, but when detected early, it has a nearly 100% cure rate. Our patients deserve medical care with the most advanced technology we can provide.” said Dr. Aaron Farberg, Chief Medical Officer of Bare Dermatology. Dr. Farberg was recently ranked by his dermatology colleagues in Newsweek Magazine as the #1 medical dermatologist in Texas and #5 in the United States.

“We are excited to together with Bare Dermatology support their efforts to provide the highest quality care to their patients through the use of Nevisense, the only FDA approved melanoma detection technology at point-of-care. SciBase is focused on addressing the need for early melanoma detection in the highest at-risk patient population in the U.S. We are expanding in the areas where melanoma rates are high and where patients have access to the Nevisense test fee schedule from Medical Administrative Contractors (First Coast of Florida and Novitas). We are pleased to collaborate with Bare Dermatology as we expand across the US to address the early detection of melanoma needs”, said Pia Renaudin, appointed Chief Executive Officer of SciBase.

SciBase strengthens US team with experienced Dermatology executive

September 4, 2023 Published by Roboticulized.com

SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders hereby announces that Dan Walker has been appointed as VP US Commercial Operations.

Dan was previously Senior Director Commercial Insights, Market Access and Field Reimbursement at Biofrontera Inc., a company focused on the Dermatology market treating actinic keratosis with PDT (Photodynamic Therapy). At Biofrontera Inc., Dan was an instrumental leader in launching the new company in the US market with their first FDA approved drug and device combination product in Dermatology.

With more than 24 years of experience in the US healthcare market, Dan has held leadership roles in Sales, Training, Commercial Operations, Commercial Insights, Key Accounts, Market Access, and Field Reimbursement. His experience building winning teams within the US Dermatology market, and deep knowledge of the US medical benefit reimbursement landscape, will be key in driving SciBase US sales and market access activities forward.

“We see Dan’s experience and drive as key in SciBase’s success in the US as we expand and build on our recent reimbursement progress with two Medicare Administrative Contractors (MACs). We have recently added employees in both Texas and California to continue to expand within reimbursement and sales. We welcome Dan to the team and look forward to further acceleration of activities in the US market,” says Tord Lendau, Chairman of the Board at SciBase.

SciBase receives increased US Medicare fee schedules for the Nevisense melanoma test

April 5, 2023 Published by Roboticulized.com

SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that two Medicare Administrative Contractors (MACs): First Coast Service Options (First Coast) and Novitas Solutions (Novitas) have published updated fee schedules for SciBase’s early detection test for melanoma (0658T). First Coast covers the state of Florida and Novitas covers the central and mid-Atlantic US and together they cover about one-third of the US Medicare population. The updated fee schedules are valid retroactively from 1^st January 2023 and are available on the MAC’s respective webpages.

“We are very pleased with the new fee schedules and more importantly, the levels will be seen as appropriate by clinicians to support the expanded use of the Nevisense test for early melanoma detection at point of care. For SciBase this is a critical decision that paves the way for further US expansion – both within the two covered regions, but also into MACs that cover other parts of the US.

We are happy to know clinicians have found Nevisense clinically valuable and useful in the management of patients. For Medicare it can also result in savings due to earlier and more accurate melanoma detection. This has been a challenging process that has taken longer than anticipated and I applaud the patience of our users. The decisions mean that Medicare patients in these regions will now have better access to the latest technology and improved accuracy when their atypical lesions are being evaluated for suspicion of melanoma,” said Simon Grant, Chief Executive Officer of SciBase.

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on April 4, 2023.

SciBase and Schweiger Dermatology Group partner to advance skin cancer detection in select New Jersey locations

March 29, 2023 Published by Roboticulized.com

SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Schweiger Dermatology group (“SDG”) to pilot Nevisense in their Freehold, NJ office. Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut. The agreement will provide Schweiger Dermatology Group’s Freehold, New Jersey practice with Nevisense, the only FDA approved test for early melanoma detection at point-of-care.

“We are excited to integrate the Nevisense test during routine skin exams in our Freehold and Verona, New Jersey offices and offer our patients the latest technology for the earliest possible detection of melanoma. Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate. Early testing and treatment are critical for improving survival rates. Providing our patients with the most advanced technology further supports our commitment to delivering the best care to our patients,” said Dr. Jason H. Miller, Medical Director for New Jersey and Long Island for Schweiger Dermatology Group.

“We are very pleased to announce our collaboration with Schweiger Dermatology Group. In addition to the early detection benefits for patients, the partnership means clinicians at Schweiger Dermatology Group’s Freehold and Verona, New Jersey offices will have access to state-of-the-art melanoma detection technology. For SciBase, we establish a further partner that helps introduce Nevisense to US payers,” said Simon Grant, Chief Executive Officer of SciBase.

New article discusses EIS as a potential clinical measure of skin barrier integrity

October 28, 2022 Published by Roboticulized.com

SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a recently published article in the journal ‘Molecular Psychiatry’, a part of Nature, named “Ectodermal origins of the skin-brain axis: a novel model for the developing brain, inflammation, and neurodevelopmental conditions” discusses that EIS may represent an alternate clinical measure of skin barrier integrity that may function as a surrogate for neurodevelopmental divergence.

The article describes Electrical impedance spectroscopy (EIS) as a recently emerged promising alternative measurement of skin barrier function. EIS is a non-invasive indicator of epidermal integrity, rapidly measuring the skin’s resistance to the flow of alternating imperceptible currents. Considering the likely differences in cell size and orientation between typical and abnormal skin, EIS has been suggested as a useful proxy for disease status. Currently, EIS has been observed to successfully differentiate between healthy, lesional and non-lesional skin in adults with AD, with these readings inversely correlating to TEWL.

In the article the authors hypothesize: “In this paper, we propose a novel hypothesis, that there is an antenatal link between skin and neurodevelopment, partially underpinned by the tissue’s shared ectodermal origin with common molecular factors. Additionally, we evaluate postnatal mediators of this skin-brain co-vulnerability, considering the role of epidermal keratinocytes and the cutaneous microbiota in cortical development. Accordingly, we hypothesize that skin barrier integrity may represent an accessible and novel biomarker to aid in the early detection of neurodevelopmental divergence. We further propose that skin barrier integrity may play a crucial role in mediating the relationship between environmental triggers of infection, immune processes, and neurodevelopment, with potential to reduce the impact of such environmental triggers by improving skin barrier integrity.”

The article is available through the following link:

https://www.nature.com/articles/s41380-022-01829-8

“This study shows the increasing interest in EIS and Nevisense and that it can become a very useful clinical measure in the management of different diseases when looking at skin barrier integrity. Previous studies have already shown that Nevisense can discriminate between patients with and without atopic dermatitis through non-lesional skin measurements and this has created the basis for the interest we see as EIS has the potential to track improvement after therapy. We believe that Nevisense and EIS have the potential to become a standard of care in this space and a very significant opportunity for SciBase”, says Simon Grant, CEO of SciBase.

SciBase receives largest electrode order from a single clinic valued at 60k€

March 24, 2022 Published by Roboticulized.com

SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has received its single largest order to date from a single clinic. The order for nearly 2,000 electrodes was received from an existing customer, a private Dermatology clinic in Germany. The order was valued at around 60k€ and will be delivered in April. The company has seen a significant increase in order volume following the announcement of an 8% increase in electrode prices from April 1.

“It is very pleasing to see one of our customers commit so strongly to utilising our product going forward. To me an order like this is the best indication that a customer believes in our technology and the value it can bring them and their patients,” says Simon Grant, CEO SciBase.

New Study published showing Nevisense impact on clinician confidence and accuracy

January 27, 2022 Published by Roboticulized.com

SciBase Holding AB (“SciBase”) (STO:SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study supporting the use of Nevisense in diagnosing melanoma has been published in “SKIN – The journal of cutaneous medicine”. The article is authored by Avani Kolla, Prof David Polsky and others from The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine in New York. The study shows that Nevisense provides valuable diagnostic guidance when evaluating atypical pigmented skin lesions.

“Melanoma is a potentially deadly form of skin cancer and has an almost 100% cure rate if caught early. While the performance of Nevisense as a diagnostic aid in the management of atypical pigmented skin lesions suspicious for melanoma has been previously demonstrated, its impact on clinician confidence in their biopsy decisions has not been described. In this pilot study, we found that mean confidence for clinicians in correctly identifying the disease diagnosis significantly increased when we added Nevisense to the evaluation of clinical and dermoscopic images of skin lesions suspicious for melanoma. Adding Nevisense to these evaluations also significantly increased diagnostic accuracy and biopsy sensitivity for melanoma,” says David Polsky, MD, PhD Alfred W. Kopf, MD Professor in the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine, NYU Langone Health.

“This study further validates Nevisense as a valuable tool for the early detection of melanoma. The article presents additional evidence that Nevisense can help clinicians of all experience levels improve their ability to accurately identify lesions that require treatment and to be more confident in their clinical management decisions”, says Simon Grant, CEO of SciBase.

Publication details:

New clinical study suggests Nevisense has a positive impact on Clinicians confidence and diagnostic accuracy for early melanoma detection
The US based study data further supports Nevisense’s clinical value for clinicians of all levels

The article is titled “Impact of Electrical Impedance Spectroscopy on Clinician Confidence and Diagnostic Accuracy in Evaluating Melanocytic Skin Lesions Suspicious for Melanoma: A Pilot Study” and evaluates whether “clinician diagnostic confidence, sensitivity, specificity and accuracy can be increased by adding EIS measurement scores to clinical and dermoscopic images of lesions clinically suspicious for melanoma”. In the study Nevisense increased clinician’s sensitivity for melanoma and dysplastic nevi from 70% to 84%. The conclusion in the article states: ” EIS increased novice and expert diagnosticians’ confidence regarding dermoscopically equivocal melanocytic lesions.”

SciBase nominating committee proposes the election of Dr Jvalini Dwarkasing as a new Board member

August 20, 2021 Published by Roboticulized.com

SciBase Holding AB (“SciBase”) (STO:SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today that the Nominating Committee proposes the election of Dr. Jvalini Dwarkasing as a new Board member at an extraordinary general meeting to be proposed by the Board of Directors of SciBase.

The nominating committee, consisting of Christer Jönsson (appointed by FourierTransorm), Iraj Arastoupour, Peter Elmvik and Tord Lendau Chairman of the Board, hereby proposes the election of Dr. Jvalini Dwarkasing as a new member of the Board to an EGM to be held later in 2021.

Dr Dwarkasing, proposed to the nominating committee by Van Herk Investments, is currently the Chief Scientific Officer at SkylineDx. She has over 10 years of life science experience with an international track record within oncology having held both research and management positions. Dr Dwarkasing has a strong academic background and a PhD in medical nutrition and pharmacology. Her driver for doing research is patient focus and how to bring science from bench to bedside. Her geographical areas of focus are the US, Europe and Australia.

The nominating committee believes that her knowledge and experience within the fields of Dermatology/Pathology, the international Dermatology industry and Dermatology networks are aligned with the future competence needs for the SciBase Board of Directors.

Tag: SciBase Holding AB